The performance of the automated Vitek 2 (bioMérieux, Inc., Marcy l'Etoile, France) antifungal susceptibility system was compared to that of broth microdilution (BMD) for the determination of MICs of various antifungal drugs. A total of 112 challenge strains and 755 clinical isolates of Candida spp. were tested against caspofungin and micafungin. An additional 452 clinical isolates of Candida albicans were tested against posaconazole. Reference BMD MIC endpoints were established after 24 h of incubation for caspofungin and micafungin and after 48 h of incubation for posaconazole. Essential agreements (EAs) between the Vitek 2 and BMD methods for caspofungin and micafungin were 99.5% and 98.6%, respectively. EA between the Vitek 2 and BMD methods was 95.6% for posaconazole. The overall categorical agreements (CAs) between the Vitek 2 system and BMD were 99.8% for caspofungin, 98.2% for micafungin, and 98.1% for posaconazole. The Vitek 2 system reliably determined caspofungin and micafungin MICs among Candida spp. and posaconazole MICs among C. albicans isolates and demonstrated excellent quantitative and qualitative agreement with the reference BMD method.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3122687 | PMC |
| http://dx.doi.org/10.1128/JCM.02517-10 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Distribution and antifungal susceptibility of species causing vulvovaginal candidiasis and urinary tract infection in Medlatec healthcare system, Ha Noi city, Vietnam in 2023.
Ther Adv Infect Dis
January 2025
Department of Medical Parasitology, Military Medical University, No. 160 Phunghung Road, Hadong District, Hanoi 100000, Vietnam.
Background: Vulvovaginal candidiasis and urinary tract infections caused by are common diseases. While the most common causative agent is , other species, such as non-, can also be responsible. Susceptibility to antifungal drugs varies among species, but there is very limited information available from Vietnam.
View Article and Find Full Text PDFPerspectives on the Use of Echinocandins in the Neonatal Intensive Care Unit.
Antibiotics (Basel)
December 2024
Neonatal Intensive Care Unit, School of Medicine, University of Ioannina, 45500 Ioannina, Greece.
The neonatal intensive care unit (NICU) population, especially low birth weight and critically ill neonates, is at risk of invasive infections, which are associated with high mortality rates and unfavorable long-term outcomes. The timely initiation of an appropriate antifungal treatment has been demonstrated to enhance the prognosis. Factors that should be considered in the choice of an antifungal agent include the causative strain, the presence and location of deep tissue infection, any previous use of antifungal prophylaxis, and the presence of implanted devices.
View Article and Find Full Text PDFGenetic and Phenotypic Intra-Clade Variation in Candida auris Isolated from Critically Ill Patients in a New York City Tertiary Care Center.
Clin Chem
January 2025
Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY, United States.
Background: Candida auris is an emerging multidrug-resistant pathogen. Interpretation of susceptibility testing can be difficult since minimum inhibitory concentration (MIC) breakpoints have not been fully established.
Methods: All C.
Evaluation of Fifteen 5,6-Dihydrotetrazolo[1,5-]quinazolines Against : Integrating In Vitro Studies, Molecular Docking, QSAR, and In Silico Toxicity Assessments.
J Fungi (Basel)
November 2024
Department of Biosciences and Biotechnologies, Graduate School of Bioresources and Bioenvironment Sciences, Kyushu University, 744 W5-674, Motooka Nishi-ku, Fukuoka 819-0395, Japan.
(), the second most prevalent Candida pathogen globally, has emerged as a major clinical threat due to its ability to develop high-level azole resistance. In this study, two new 5,6-dihydrotetrazolo[1,5-]quinazoline derivatives ( and ) were synthesized and characterized using IR, LC-MS, H, and C NMR spectra. Along with 13 previously reported analogues, these compounds underwent in vitro antifungal testing against clinical isolates using a serial dilution method (0.
View Article and Find Full Text PDFSevere cutaneous adverse reactions associated with antifungal agents: a pharmacovigilance analysis based on the FDA Adverse Event Reporting System (FAERS) database.
Expert Opin Drug Saf
January 2025
Department of Pharmacy, West China Hospital, Sichuan University, Chengdu, China.
Background: The aim of this study was to explore the risk of severe cutaneous adverse reactions (SCARs) caused by different antifungal drugs in the real world.
Methods: We extracted the data from the FDA Adverse Event Reporting System (FAERS) from January 2004 to December 2022 and performed disproportionality analyses to characterize the signal differences of antifungal agents-related SCARs.
Results: A total of 952 antifungals-related SCARs were identified.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!